Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Asset Writedowns and Impairment: 2012-2024

Historic Asset Writedowns and Impairment for OptimizeRx (OPRX) over the last 7 years, with FY2024 value amounting to $7.5 million.

  • OptimizeRx's Asset Writedowns and Impairment rose 1753.99% to $7.4 million in Q4 2024 from the same period last year, while for Jun 2025 it was $7.4 million, marking a year-over-year increase of 1278.36%. This contributed to the annual value of $7.5 million for FY2024, which is 1114.57% up from last year.
  • According to the latest figures from FY2024, OptimizeRx's Asset Writedowns and Impairment is $7.5 million, which was up 1114.57% from $6.7 million recorded in FY2023.
  • OptimizeRx's 5-year Asset Writedowns and Impairment high stood at $7.5 million for FY2024, and its period low was $80000.0 during FY2021.
  • Its 5-year average for Asset Writedowns and Impairment is $3.0 million, with a median of $363512.0 in 2022.
  • As far as peak fluctuations go, OptimizeRx's Asset Writedowns and Impairment plummeted by 6000.0% in 2021, and later skyrocketed by 175358.39% in 2023.
  • Annual analysis of 5 years shows OptimizeRx's Asset Writedowns and Impairment stood at $200000.0 in 2020, then crashed by 60.0% to $80000.0 in 2021, then skyrocketed by 354.39% to $363512.0 in 2022, then skyrocketed by 1753.58% to $6.7 million in 2023, then rose by 11.15% to $7.5 million in 2024.
  • Its Asset Writedowns and Impairment was $7.5 million in FY2024, compared to $6.7 million in FY2023 and $363512.0 in FY2022.